Late breaking abstracts: Therapies – clinical testing
LB111 – LB116
- LB111: A study of the relationship between drug efficacy/toxicity and platinum-DNA adduct formation in pre- and post-infusion lymphocyte samples from patients receiving platinum-based chemotherapy
- LB112: Gemcitabine with or without prophylactic weight-adjusted Dalteparin (WAD) in patients with advanced or metastatic pancreatic cancer (APC): a multicentre, randomised phase IIB trial (the UK FRAGEM study)
- LB113: Unplanned hospital admissions as an early surrogate indicator of patient (pt) attrition in phase I trials
- LB114: A novel role for Nutlin-3 in the mammalian DNA-damage response
- LB115: A two stage multicentre phase II study of Imatinib in the treatment of patients with c-kit positive metastatic uvEal Melanoma (ITEM)
- LB116: Efficacy and toxicities of a reduced dose sunitinib regimen in metastatic renal cell carcinoma
